Cedars-Sinai Cancer | Strategic Alliance Partners

February 21, 2020

Jean Lopategui, MD, discusses the use of liquid biopsies in lung cancer.

February 20, 2020

Ronald Natale, MD, expands on the recent developments with immunotherapy in advanced non–small cell lung cancer.

February 20, 2020

Amin J. Mirhadi, MD, discusses novel radiation approaches that are being used in non–small cell lung cancer.

February 20, 2020

Alain C. Mita, MD, discusses the impact of checkpoint inhibitors on the small cell lung cancer treatment paradigm.

February 19, 2020

Karen Reckamp, MD, MS, highlights the different agents that have been developed to target rarer abnormalities in non–small cell lung cancer.

February 19, 2020

Stephen J. Freedland, MD, discusses a real-world analysis of enzalutamide in metastatic castration-resistant prostate cancer.

February 15, 2020

Robert A. Figlin, MD, discusses the evolving treatment landscape of renal cell carcinoma (RCC).

May 09, 2019

Robert A. Figlin, MD, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology/Oncology, deputy director, Integrated Oncology Service Line, and professor of Biomedical Sciences, Medicine, at Cedars-Sinai Medical Center, discusses the toxicity profiles of combinations of immune checkpoint inhibitors and VEGF TKIs in renal cell carcinoma (RCC), as well as research being done to validate potential biomarkers in the space.

April 22, 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the promise of immunotherapy plus TKI combinations in the treatment of patients with renal cell carcinoma.

April 16, 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses next steps for research in the treatment of patients with metastatic renal cell carcinoma.

April 15, 2019

Robert A. Figlin, MD, highlights advances made with immunotherapy in renal cell carcinoma and sheds light on the challenges that remain.

March 08, 2019

Edwin M. Posadas, MD, FACP, discusses recent prostate cancer data and sheds light on where emerging therapies may fit into this landscape.

February 08, 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the future of treatment for patients with renal cell carcinoma.

January 10, 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses considerations when combining TKIs and immunotherapy agents in the management of advanced renal cell carcinoma.

September 23, 2018

Using wearable activity monitors may eventually supplement standard assessments of performance status and functionality that could inform clinicians, especially because objective evaluation of performance status is difficult to determine.

September 19, 2018

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses the future treatment landscape of prostate cancer.

September 13, 2018

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses unmet needs in prostate cancer.

September 12, 2018

Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the potential combination of immunotherapy and tyrosine kinase inhibitors in metastatic renal cell carcinoma.

September 10, 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the future of kidney cancer treatment.

April 10, 2018

Hyung L. Kim, MD, discusses perioperative systemic therapy for patients with kidney cancer.